A big STEP for treatment of heart failure with preserved ejection fraction
Davies, Melanie
Davies, Melanie
Abstract
In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2023-08-17
Type
Article
Subject
Collections
Citation
Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Dhingra, N. K., & Kosiborod, M. N. (2023). A big STEP for treatment of heart failure with preserved ejection fraction. Cell metabolism, S1550-4131(23)00298-X. Advance online publication. https://doi.org/10.1016/j.cmet.2023.08.003